Veracyte CEO and leadership

Bonnie H. Anderson is Chairman of the Board, Chief Executive Officer and President of Veracyte, a pioneering genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in healthcare – enabling patients to get diagnosed sooner and avoid invasive surgeries and other costly procedures. Her career spans nearly 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008, took the company public in 2013 and has spearheaded Veracyte’s commercialization successes to date. Veracyte’s genomic tests are setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of thousands of patients avoid unnecessary surgery and other costly procedures. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. In 2015, Fast Company magazine named Ms. Anderson to its “100 Most Creative People in Business” list. She was named one of the “Most Influential Women in Bay Area Business” (2013) and one of the “Bay Area’s Most Admired CEOs” (2014) by the San Francisco Business Times, and has also received the Silicon Valley Business Journal’s “Women of Influence” award (2013).

Giulia Kennedy is a Chief Scientific Officer at VERACYTE, INC..

Bonnie H. Anderson is Chairman of the Board, Chief Executive Officer and President of Veracyte, a pioneering genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in healthcare – enabling patients to get diagnosed sooner and avoid invasive surgeries and other costly procedures. Her career spans nearly 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008, took the company public in 2013 and has spearheaded Veracyte’s commercialization successes to date. Veracyte’s genomic tests are setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of thousands of patients avoid unnecessary surgery and other costly procedures. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. In 2015, Fast Company magazine named Ms. Anderson to its “100 Most Creative People in Business” list. She was named one of the “Most Influential Women in Bay Area Business” (2013) and one of the “Bay Area’s Most Admired CEOs” (2014) by the San Francisco Business Times, and has also received the Silicon Valley Business Journal’s “Women of Influence” award (2013).

Bonnie H. Anderson is Chairman of the Board, Chief Executive Officer and President of Veracyte, a pioneering genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in healthcare – enabling patients to get diagnosed sooner and avoid invasive surgeries and other costly procedures. Her career spans nearly 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008, took the company public in 2013 and has spearheaded Veracyte’s commercialization successes to date. Veracyte’s genomic tests are setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of thousands of patients avoid unnecessary surgery and other costly procedures. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. In 2015, Fast Company magazine named Ms. Anderson to its “100 Most Creative People in Business” list. She was named one of the “Most Influential Women in Bay Area Business” (2013) and one of the “Bay Area’s Most Admired CEOs” (2014) by the San Francisco Business Times, and has also received the Silicon Valley Business Journal’s “Women of Influence” award (2013).